The PI3K/mTOR inhibitor CMG002 was demonstrated to re-sensitize chemo-resistant ovarian cancer cells (paclitaxel-resistant SKpac17 and A2780cis) to chemotherapies in vitro, and showed a marked decrease in tumor growth in xenograft mouse models of each cell line, either alone or in combination with paclitaxel or cisplatin[128]. This evidence concerns the gene PIK3CD and ovarian cancer.